Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 3 de 3
Filter
Add more filters











Database
Language
Publication year range
1.
Protein Eng Des Sel ; 23(4): 299-309, 2010 Apr.
Article in English | MEDLINE | ID: mdl-20150179

ABSTRACT

A recombinant soluble version of the human high-affinity receptor for IgG, rh-FcgammaRIA or CD64A, was expressed in mammalian cells and purified from their conditioned media. As assessed by circular dichroism, size exclusion chromatography and dynamic light scattering, incubation of rh-FcgammaRIA at 37 degrees C resulted in time-dependent formation of soluble aggregates caused by protein unfolding and loss of native structure. Aggregate formation was irreversible, temperature-dependent and was independent of rh-FcgammaRIA concentration. Aggregated rh-FcgammaRIA lost its ability to inhibit immune complex precipitation and failed to bind to IgG-Sepharose. Addition of human IgG1 to rh-FcgammaRIA prior to incubation at 37 degrees C blocked the formation of rh-FcgammaRIA aggregates. Production of soluble monomeric rh-FcgammaRIA was limited by aggregate formation during cell culture. Substitution of the membrane distal D1 Ig domain of FcgammaRIA with the D1 Ig domain of FcgammaRIIIA or CD16A resulted in a chimeric receptor, FcgammaR3A1A, with enhanced temperature stability. Relative to native rh-FcgammaRIA, FcgammaR3A1A exhibited less aggregation in Chinese hamster ovary cell-conditioned media or when purified receptor was incubated for up to 24 h at 37 degrees C. Both receptors bound to immobilized human IgG1 with high affinity and were equipotent at blockade of immune complex-mediated cytokine production from cultured mast cells. Equivalent dose-dependent reductions in edema and neutrophil infiltration in the cutaneous Arthus reaction in mice were noted for rh-FcgammaRIA and FcgammaR3A1A. These data demonstrate that the D1 Ig domains of FcgammaRIA and FcgammaRIIIA are functionally interchangeable and further suggest that the chimeric receptor FcgammaR3A1A is an effective inhibitor of type III hypersensitivity in mice.


Subject(s)
Receptors, IgG/chemistry , Animals , CHO Cells , Cricetinae , Cricetulus , Humans , Mice , Mice, Inbred BALB C , Protein Structure, Tertiary , Receptors, IgG/immunology , Receptors, IgG/metabolism
2.
Hepatology ; 44(4): 896-906, 2006 Oct.
Article in English | MEDLINE | ID: mdl-17006906

ABSTRACT

Interleukin-28A (IL-28A), IL-28B and IL-29 are a family of class II cytokines that stimulate antiviral responses through a heterodimeric receptor that is distinct from the type I interferon (IFN) receptor. To better understand how this newly described family of cytokines regulates the antiviral state, we compared various cellular responses elicited by IL-29 and IFN-alpha. Here we show that these cytokines stimulate similar patterns of signal transducer and activator of transcription 1 (STAT-1), -2, -3, and -5 phosphorylation and nearly identical patterns of gene expression when analyzed in two distinct cell types by microarray analysis. Interestingly, the IL-29 receptor is preferentially expressed on primary hepatocytes within normal liver and pegylated forms of IL-29 and IFN-alpha induced equivalent 2'5' oligoadenylate synthetase (OAS) and MX1 gene expression in this cell type. Pegylated IL-29 also produced a significant reduction in human hepatitis B and hepatitis C viral load in vitro and reduced the cytopathic effect caused by the fully replicating flavivirus, West Nile virus. In conclusion, IL-29 and IFN-alpha stimulate identical antiviral responses despite their utilization of different receptors. This fact, combined with significant receptor expression in hepatitis virus-infected livers, suggests that IL-29 may have therapeutic value against chronic viral hepatitis in human patients.


Subject(s)
Antiviral Agents/pharmacology , Cytokines/pharmacology , Gene Expression Regulation, Viral/drug effects , Hepatitis, Viral, Human/drug therapy , Interferon-alpha/pharmacology , Interleukins/pharmacology , Animals , Antiviral Agents/adverse effects , Antiviral Agents/therapeutic use , CHO Cells/drug effects , Cell Line/drug effects , Cricetinae , Cricetulus , Cytokines/therapeutic use , Flavivirus/genetics , Hepacivirus/genetics , Hepatitis B virus/genetics , Hepatitis, Viral, Human/virology , Hepatocytes/metabolism , Hepatocytes/virology , Humans , Interferon-alpha/adverse effects , Interferon-alpha/therapeutic use , Interferons , Interleukins/therapeutic use , Oligonucleotide Array Sequence Analysis , Phosphorylation , RNA/analysis , RNA/metabolism , Receptors, Interleukin/metabolism , STAT1 Transcription Factor/metabolism , Viral Load , Virus Replication/drug effects
3.
Nat Immunol ; 4(1): 63-8, 2003 Jan.
Article in English | MEDLINE | ID: mdl-12469119

ABSTRACT

Cytokines play a critical role in modulating the innate and adaptive immune systems. Here, we have identified from the human genomic sequence a family of three cytokines, designated interleukin 28A (IL-28A), IL-28B and IL-29, that are distantly related to type I interferons (IFNs) and the IL-10 family. We found that like type I IFNs, IL-28 and IL-29 were induced by viral infection and showed antiviral activity. However, IL-28 and IL-29 interacted with a heterodimeric class II cytokine receptor that consisted of IL-10 receptor beta (IL-10Rbeta) and an orphan class II receptor chain, designated IL-28Ralpha. This newly described cytokine family may serve as an alternative to type I IFNs in providing immunity to viral infection.


Subject(s)
Interleukins/genetics , Interleukins/metabolism , Receptors, Cytokine/genetics , Receptors, Cytokine/metabolism , Amino Acid Sequence , Animals , COS Cells , Cloning, Molecular , Cytokines , Gene Expression , Humans , In Vitro Techniques , Interferons , Molecular Sequence Data , Protein Subunits , RNA/genetics , RNA/metabolism , Receptors, Cytokine/chemistry , Recombinant Proteins/chemistry , Recombinant Proteins/genetics , Recombinant Proteins/metabolism , Sequence Homology, Amino Acid , Signal Transduction , Virus Diseases/immunology
SELECTION OF CITATIONS
SEARCH DETAIL